Introduction
Ligation of a wide variety of cell surface receptors leads to the generation of the PIP 3 lipid second messenger, which affects cell growth, cell cycle progression, survival, intracellular traffic, cytoskeletal changes and migration (Vanhaesebroeck et al, 2001; Hawkins et al, 2006) . PIP 3 targets diverse downstream effector proteins through interaction with pleckstrin homology (PH) domains present in Ser/Thr kinases (such as Akt/PKB), Tyr kinases (such as Btk), adaptor proteins (such as Gab2) and regulators of small GTPases (such as guanosine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs)) (Vanhaesebroeck et al, 2001; Hawkins et al, 2006) . PIP 3 action in cells is counteracted by lipid phosphatases, among which PTEN is the most extensively investigated. Indeed, PTEN is mutationally inactivated in a wide variety of cancers, contributing to the constitutive activation of the PI3K pathway in these cells (Leslie and Downes, 2004; Parsons, 2004; Sansal and Sellers, 2004; Cully et al, 2006) . Despite its importance, however, a clear picture on the biochemical regulation of PTEN, its responsiveness to extracellular stimuli and its control by PI3K itself has yet to emerge (Leslie and Downes, 2004; Gericke et al, 2006) . Processes that have been implicated in PTEN regulation include oxidation, protein:protein interaction and phosphorylation on Tyr by unknown kinases (Koul et al, 2002; Sanchez et al, 2005) or phosphorylation on Ser/Thr, for example by CK2 and GSK3 (Vazquez et al, 2000; Torres and Pulido, 2001; Miller et al, 2002) . All of these events may impact on PTEN stability and subcellular localisation. Recently, a role for RhoA and its effector kinase ROCK in positive regulation of PTEN activity has been reported (Li et al, 2005; Sanchez et al, 2005) . Indeed, ROCK can increase the phosphorylation and activity of PTEN, through an unknown mechanism but most likely involving a physical interaction with PTEN (Li et al, 2005; Meili et al, 2005) . The upstream signals that control this RhoA/ROCK/PTEN pathway are unknown. It is also unclear whether this pathway is operational in cells under non-overexpression conditions. Downstream of tyrosine kinases and Ras, PIP 3 is produced by the class IA subset of PI3Ks. These are heterodimers made up of a 110 kDa catalytic subunit (p110a, p110b and p110d) in complex with one of five regulatory subunits (collectively called the 'p85s'). Whereas p110a and p110b are found in most tissues, the expression of p110d is most abundant in leukocytes.
We previously presented evidence that the class IA PI3K isoforms have nonredundant functions downstream of the receptors for colony-stimulating factor-1 (CSF-1) in macrophages (Vanhaesebroeck et al, 1999b) and epidermal growth factor (EGF) in breast cancer cell lines (Sawyer et al, 2003) . Using microinjection of p110d-selective antibodies in the immortalised BAC1.2F5 macrophage cell line (Morgan et al, 1987) , we showed that p110d controls actin reorganisation and chemotaxis downstream of the CSF-1 receptor (CSF-1R) (Vanhaesebroeck et al, 1999b) . The intracellular signalling mechanism by which p110d achieves its biological functions in these cells has thus far not been delineated. Here we use genetic and pharmacological approaches to dissect the molecular mechanism of p110d signalling, using primary mouse macrophages as well as other cell types that express p110d, including breast cancer cell lines (Sawyer et al, 2003) . We report the unexpected finding that p110d inactivates PTEN through a pathway involving RhoA and ROCK. This inhibition of PTEN is essential for p110d to exert its biological
Results

Derivation of macrophages with inactive p110 d
Bone-marrow-derived macrophages (BMMs) were derived from wild-type (WT) mice, or from mice in which both p110d alleles are replaced by a kinase-dead version of p110d (called p110d D910A ), as a result of knock-in mouse gene targeting (Okkenhaug et al, 2002) . Pharmacological intervention with p110d was achieved by the use of IC87114, a small molecule inhibitor with selectivity for p110d (Sadhu et al, 2003) .
We first tested the effect of p110d inactivation on BMM biology. Culture of bone marrow precursor cells from WT and d D910A/D910A mice in the presence of CSF-1 gave rise to similar numbers of mature BMMs (data not shown), expressing similar levels of the CSF-1R and the macrophage-specific marker F4/80 (Supplementary Figure S1) . Mutant BMMs did not show compensatory expression of nontargeted class I PI3K isoforms (Supplementary Figure S1b) or other genes (as assessed by gene array studies; Clotilde Billottet and Bart Vanhaesebroeck, unpublished data). Under proliferating conditions in the presence of CSF-1, no changes in cell morphology, size and actin cytoskeleton were observed (data not shown). These data indicate that inactivation of p110d has no major effects on the differentiation of bone marrow precursor BMMs upon gradient stimulation with CSF-1. BMMs were exposed to a gradient of CSF-1, delivered via a microtip, for the indicated time periods, followed by fixation and indirect immunofluorescence using an anti-PIP 3 antibody (scale bar: 30 mm). Cells with the pan-PI3K inhibitor LY294002 were used as control. (C) Chemotaxis in BMMs exposed to a gradient of CSF-1 in Dunn chambers, monitored for 16 h by time-lapse microscopy. The cell tracks from three separate experiments were merged into a single file for analysis. Circular histograms (upper panels) show the proportion of cells migrating into each of 20 segments of the angular trajectory plot (measured when each cell migrated past a horizon of 30 mm from its starting point with the source of CSF-1 at the top). Arrows indicate significant mean directionality of the cell population. The shaded area marks the 95% confidence intervals of statistical significance. n ¼ x (y) below the histograms indicates the number of cells migrated past the particular horizon (x), out of the total number of cells tracked (y). Similar chemotaxis plots were obtained for horizon limits of 50, 80 and 100 mm, although the cell numbers varied (not shown Figure S2a) .
Upon stimulation with a uniform and saturating concentration of CSF-1 (30 ng/ml), d
D910A/D910A cells also showed reduced actin polymerisation, membrane ruffling and cell spreading (Figure 1A and Supplementary Figure S2a, b) .
Upon gradient stimulation with CSF-1, administered by a micropipette ( Figure 1B ), WT cells rapidly polarised towards the source of CSF-1 and accumulated PIP 3 at the leading edge. At very early time points, a number of cells in (Rosivatz et al, 2007) , stimulated with CSF-1 (30 ng/ml) for the indicated time points followed by WB for P-Akt (S473) or GAPDH. Two independent experiments were performed with similar results. (B) Effect of p110d inactivation on Tyr phosphorylation of PTEN. BMMs were stimulated with CSF-1 (30 ng/ml) for the indicated time points, followed by IP of PTEN and WB for P-Tyr or total PTEN. Bottom panel: ratio of WB signal of Tyr-phosphorylated PTEN over that of total PTEN. Two independent experiments were performed with similar results. (C) Effect of p110d inactivation on PTEN lipid phosphatase activity. PTEN was immunoprecipitated from BMM lysates and its PIP 3 phosphatase activity determined using L-a-phosphatidylinositol(3,4,5)-triphosphate as a substrate and the Biomol Green reagent. One representative experiment out of two independent experiments carried out in triplicate is shown (**Po0.01). The blot above the graph shows WB of PTEN in the BMM lysates used for PTEN immunoprecipitation. (D) PTEN immunoprecipitates were incubated for 30 min with GST-SHP1 or with buffer control, followed by measurement of Tyr phosphorylation and lipid phosphatase activity of PTEN. (E) PTEN activity induced by IC87114 in breast cancer lines. MDA-MB-231 or T47D cancer cells were pretreated with 5 mM of IC87114 or vehicle for 60 min, followed by PTEN IP and determination of its PIP 3 phosphatase activity by ELISA (Echelon). One representative experiment out of two independent experiments carried out in triplicate is shown (*Po0.05). The blot above the graph shows a WB of PTEN in the lysates used for PTEN immunoprecipitation. D910A/D910A BMM cultures polarised but this was followed by quick retraction, so that at later time points polarised cells were no longer observed ( Figure 1B) . Similarly, IC87114 treatment of BMMs derived from WT mice, transgenic for an intracellular PIP 3 /PI(3,4)P 2 -binding GFPAkt-PH probe (Nishio et al, 2007) , blocked CSF-1-induced GFP recruitment to the leading edge (Supplementary Figure S2c) . Migration induced by a uniform concentration of CSF-1 was mildly affected upon p110d inactivation. Although WT and d D910A/D910A BMMs migrated with the same speed (Supplementary Figure S2d) , the latter cells stayed closer to their starting point, as revealed by plots whereby the number of cells that migrated past a given distance from their point of origin is expressed, relative to the total number of cells tracked (Supplementary Figure S2d , bottom graph).
Chemotaxis of BMMs towards a gradient of CSF-1 in Dunn chemotaxis chambers was blocked by genetic or pharmacological inactivation of p110d ( Figure 1C ). Also under these conditions of directional migration, p110d inactivation led to a reduction in the number of cells that migrated past a given distance from their point of origin ( Figure 1D ).
In fully differentiated BMMs, inactivation of p110d led to reduced CSF-1-induced DNA synthesis, especially at higher concentrations of CSF-1 ( Figure 1E ). Treatment with IC87114 also decreased DNA synthesis of WT BMMs to the levels seen in d D910A/D910A cells, but did not affect DNA synthesis of the latter ( Figure 1E ). The pan-PI3K inhibitor LY294002 further reduced DNA synthesis of d D910A/D910A and WT cells ( Figure 1E ), suggesting that the remaining DNA synthesis in the absence of p110d is controlled by PI3K isoforms other than p110d. However, it is also possible that inhibition of non-PI3K signalling proteins (such as mTOR) by LY294002 (Knight et al, 2006) contributes to the antiproliferative effect of this compound.
Active p110d suppresses PTEN lipid phosphatase activity As expected, CSF-1-induced Akt phosphorylation was reduced in d D910A/D910A cells ( Figure 2A ), indicative for reduced PIP 3 production in these cells upon CSF-1 stimulation. We aimed to overcome this effect of p110d inactivation by inhibiting PTEN, a major PIP 3 phosphatase. Pretreatment with VO-OHpic (3-hydroxypicolinate vanadium(IV) complex), a selective small molecule inhibitor of PTEN (Rosivatz et al, 2007) , partially restored CSF-1-induced Akt phosphorylation in d D910A/D910A cells ( Figure 2A ). The regulation of PTEN is complex and involves phosphorylation on tyrosine (Tyr) by unknown kinases (Koul et al, 2002; Sanchez et al, 2005) and on Ser/Thr, possibly by CK2, GSK3 and other kinases (Vazquez et al, 2000; Miller et al, 2002) . Previous work has also implicated a RhoA/ROCK pathway in the control of PTEN whereby the Ser/Thr kinase ROCK activates PTEN, through an unknown mechanism (Li et al, 2005; Meili et al, 2005; Sanchez et al, 2005) . Upstream signalling pathways controlling this RhoA/PTEN axis are also unknown.
Genetic or pharmacological inactivation of p110d led to increased (yet still low) Tyr phosphorylation of PTEN, both under basal and CSF-1-stimulated conditions ( Figure 2B ; Supplementary Figure S3a ). Ser/Thr phosphorylation of PTEN was not affected under those conditions (Supplementary Figure S3b) .
Inactivation of p110d also led to increased PTEN activity under basal conditions ( Figure 2C ). CSF-1 stimulation did not affect PTEN activity in cells with inactive p110d, in contrast to WT cells in which CSF-1 stimulation reduced PTEN activity ( Figure 2C ). Treatment of PTEN, immunoprecipitated from cells with inactive p110d, with the tyrosine phosphatase SHP1 reduced PTEN activity to the levels seen in WT cells ( Figure 2D ). This indicates a correlation between increased Tyr phosphorylation and PTEN hyperactivity upon p110d inactivation.
PTEN activity was also constitutively increased in brain tissues from mice expressing inactive p110d (data not shown). Moreover, short-term treatment of p110d-positive breast cancer cell lines with IC87114 also led to increased PTEN activity ( Figure 2E ). These data indicate that p110d action inhibits PTEN activity.
p110d negatively regulates RhoA
To investigate how p110d could affect PTEN activity, we first investigated the effect of p110d inactivation on early signalling induced by CSF-1. Akt phosphorylation upon stimulation of d D910A/D910A BMMs with a saturating dose of CSF-1 (30 ng/ml) was reduced by approximately 50% (Figures 2A and 3A) , whereas Erk phosphorylation was unaffected ( Figure 3A and Supplementary Figure S4a Compared to WT cells, CSF-1-induced GTP loading of Rac1 was decreased both in d D910A/D910A and IC87114-treated WT BMMs ( Figure 3B and Supplementary Figure S4b ). These observations are in line with the known positive role of PI3K in the regulation of Akt and Rac1 (Vanhaesebroeck et al, 2001; Welch et al, 2003) .
Surprisingly, both basal as well as CSF-1-stimulated levels of RhoA-GTP were significantly increased in d
BMMs, compared to WT cells ( Figure 3C and Supplementary Figure S4c) . Pretreatment of WT cells with IC87114 also increased RhoA-GTP ( Figure 3C and Supplementary Figure S4c) . A similar increase in RhoA-GTP was also observed in CSF-1-stimulated BAC1.2F.5 macrophages and EGF-treated MDA-MB-231 and T47D p110d-expressing breast cancer cell lines (Sawyer et al, 2003) in response to IC87114 ( Figure 3C and Supplementary Figure S4d mice (data not shown). These data imply that, under normal conditions, p110d activity suppresses RhoA function in cells.
RhoA and Rac1 have been shown to oppose each other in several biological settings, and low cellular levels of Rac-GTP most often correlate with high levels of RhoA-GTP, and vice versa (Sander et al, 1999; Raftopoulou and Hall, 2004 ). This appears not to be the case in BMMs given that basal RhoA-GTP levels were increased in p110d mutant BMMs, without an effect on basal Rac1-GTP levels ( Figure 3B and C). This suggests that p110d-driven negative regulation of RhoA in these cells under basal conditions is independent of Rac1.
Inhibition of ROCK overcomes the biological effects of p110d inactivation
We next set out to investigate the importance of the increased RhoA activity in the biological responses controlled by p110d and regulation of PTEN. An important effector of RhoA-GTP is the Ser/Thr kinase ROCK (Riento and Ridley, 2003) , which is sensitive to Y27632 (Uehata et al, 1997; Nobes and Hall, 1999; Ishizaki et al, 2000) . Treatment of d D910A/D910A BMMs with Y27632 reverted p110d phenotypes to those of WT cells. This included the capacity of these cells to undergo CSF-1-induced cell polarisation and accumulation of PIP 3 at the leading edge ( Figure 4A ), chemotaxis ( Figure 4B ) and migration in a wound-healing assay (Supplementary Figure S5a) . Y27632 also partially recovered the defects in Akt phosphorylation ( Figure 4C ) and DNA synthesis ( Figure 4D) , and blocked the increase in Tyr phosphorylation ( Figure 4E ) and lipid phosphatase activity of PTEN ( Figure 4F ). Y27632 also inhibited the increased phosphorylation of MLC, a downstream target of ROCK, observed in d D910A/D910A cells (Supplementary Figure S5b) .
Alternative ways to interfere with Rho/ROCK pathways had similar effects as Y27632. For example, H1152, a ROCK inhibitor from a different chemical class to Y27632 (Sasaki et al, 2002) , increased Akt phosphorylation in d These data are consistent with a model that inactivation of p110d leads to enhanced ROCK activity, as a consequence of increased RhoA-GTP levels, contributing to the observed phenotypes.
p110d inactivation leads to reduced p190RhoGAP activity RhoA activity could be inhibited by p110d either through inhibition of a GEF or activation of GAP. Given that PI3K-dependent Rho-GEFs have not been reported, we first focused on the activity of p190RhoGAP, one of the key regulators of RhoA (Ren et al, 1999 (Ren et al, , 2000 Arthur and Burridge, 2001; Wakatsuki et al, 2003; Continolo et al, 2005) . The in vitro GAP activity of p190RhoGAP immunoprecipitated from d D910A/D910A BMMs under CSF-1-starved conditions towards RhoA was significantly reduced ( Figure 5A ). Given that the expression of p190RhoGAP was not altered in d
BMMs ( Figure 5A , lower panel), this observation suggests an intrinsic change in p190RhoGAP in these cells. This was indeed the case, as p190RhoGAP showed reduced basal and CSF-1-stimulated Tyr phosphorylation in d D910A/D910A BMMs ( Figure 5B ).
The data above are indicative of defective Tyr kinase signalling downstream of the CSF1R upon p110d inactivation. p190RhoGAP is known to be phosphorylated and activated in an Src-dependent manner (Zrihan-Licht et al, 2000) , via a complex mechanism that also involves PYK2, a FAK Tyr kinase homologue expressed in leucocytes (Ganju et al, 1997) . Indeed, PYK2 has been reported to activate Src (Dikic et al, 1996) and to bind constitutively to p190RhoGAP, facilitating the activation of the latter by Src (Zrihan-Licht et al, 2000) . Complex formation between PYK2 and p190RhoGAP was unaltered in d D910A/D910A BMMs (Supplementary Figure S6a) , both under basal and CSF-1-stimulated conditions. However, CSF-1-induced Tyr phosphorylation of PYK2 ( Figure 5C and Supplementary Figure S6b ) was reduced in d D910A/D910A cells and IC87114-treated WT BMMs. Likewise, also Tyr phosphorylation of Src was decreased under these conditions ( Figure 5D and Supplementary Figure S6c) .
Taken together, these results are consistent with a model in which p110d activity leads to increased PYK2/Src Tyr phosphorylation and p190RhoGAP activity, leading to decreased RhoA-GTP levels. Conversely, inactivation of p110d leads to increased RhoA activity (schematically shown in Figure 8 ).
p110 d inactivation leads to reduced association of cytosolic RhoA with p27
RhoA can also be regulated by p27, a member of the Cip/Kip family of cyclin-dependent kinase inhibitors (Besson et al, 2004a, b) . Indeed, cytoplasmic p27 has been reported to bind and inhibit RhoA, by blocking its interaction with cytoplasmic RhoGEFs (Besson et al, 2004b) . Akt is one of the regulators of p27, and reduction in Akt activity can lead to accumulation of p27 in the nucleus, contributing to inhibition of cell cycle progression (Zhou et al, 2001; Liang et al, 2002; Shin et al, 2002; Viglietto et al, 2002) .
In CSF-1-starved BMMs, the ratios of cytosolic versus nuclear p27 were not significantly different between WT and d D910A/D910A cells ( Figure 6A , black bars in lower bar Figure 3 Effect of p110d inactivation on CSF-1-induced activation of protein kinases and small GTPases. (A) Effect of genetic or pharmacological inactivation of p110d on CSF-1-induced phosphorylation of Akt and Erk1/2 in BMMs. Top graphs: the indicated BMMs were stimulated with 30 ng/ml CSF-1 for different time points, followed by analysis of phosphorylation of Akt (on T308 and S473) or Erk1/2 (on T202/Y204) by WB of total cell lysates (80 mg/lane). Graphs represent the mean7s.e.m. of three separate experiments. Bottom graphs: WT BMMs were incubated with the indicated concentrations of IC87114 30 min before stimulation with CSF-1 (30 ng/ml, 5 min). Akt and Erk1/2 phosphorylation were assessed by WB of total cell lysates (80 mg/lane). Graphs represent the mean7s.e.m. of three separate experiments.
(B) Effect of genetic or pharmacological inactivation of p110d on basal and CSF-1-induced Rac1 activation in BMMs. Equal volumes of cell lysates of the indicated BMMs were subjected to pull down assay with GTP-PBD, followed by detection of precipitated Rac1 by WB. Total cell lysates were resolved on the same SDS-PAGE gel and immunoblotted for Rac1. Graphs represent the mean7s.e.m. of three separate experiments. (C) Effect of genetic or pharmacological inactivation of p110d on basal and stimulus-induced RhoA activation in macrophages and breast cancer lines. BMMs or BAC1.2.F5 cells were stimulated with CSF-1 (30 ng/ml), whereas MDA-MB-231 or T47D breast cancer cells were stimulated with EGF (50 ng/ml). When indicated, cells were pretreated with IC87114 (5 mM, 1 h). Equal volumes of cell lysates of the indicated BMMs or breast cancer cell lines were subjected to pull down assay with GST-RBD, followed by WB detection of precipitated RhoA. Total cell lysates were resolved on the same SDS-PAGE gel and immunoblotted for RhoA. Graphs for BMMs represent the mean7s.e.m. of three separate experiments. For breast cancer cell lines, two independent experiments were performed with similar results. BMMs ( Figure 6A ). This suggests that in d D910A/D910A cells, less p27 is available in the cytosol to bind RhoA. In line with these observations, the amount of p27 co-immunoprecipitated with cytosolic RhoA, unlike in WT cells, did not increase in d D910A/D910A BMMs upon CSF-1 stimulation ( Figure 6B ).
Y27632 reversed the effect of p110d inhibition, and increased the ratio of cytosolic versus nuclear p27 in d D910A/D910A BMMs, without an effect on WT cells (Supplementary Figure 7) .
Taken together, these data are compatible with a model whereby the reduction in p110d activity impairs Akt activation, resulting in less p27 being available in the cytoplasm of d D910A/D910A BMMs to bind RhoA, facilitating its activation (schematically shown in Figure 8 ). Relative contribution of PYK2/Src-and p27-driven mechanisms in the regulation of RhoA activity We next examined the relative contribution of the PYK2/Src and p27 pathways in controlling RhoA-GTP levels. This was carried out in WT cells by pharmacological inhibition of Src or suppression of expression of PYK2 and/or p27 by siRNA, followed by assessment of RhoA levels, and comparing these with the RhoA-GTP levels in d D910A/D910A cells. BMMs were stimulated with CSF-1 (30 ng/ml) for the indicated time points, followed by isolation of cytosolic and nuclear fractions and WB for p27, tubulin (marker for cytosol) or retinoblastoma protein (Rb; marker for nucleus). Bottom panel: ratio of WB signal of cytosolic vs nuclear p27. (B) Top panel: RhoA was immunoprecipitated from the cytosolic fraction of BMMs using a monoclonal antibody, followed by WB for p27 or RhoA. Bottom panel: ratio of WB signal of cytosolic p27 over that of cytosolic RhoA. Two independent experiments were performed with similar results. Figure S8a) . Inhibition of Src activity also made a significant, but less comprehensive contribution to the CSF-1-induced increase in RhoA-GTP ( Figure 7A , right panel and Supplementary Figure S8a) .
Under basal conditions, reduction of PYK2 expression in WT cells led to an increase in RhoA-GTP levels almost reaching those observed in d D910A/D910A BMMs ( Figure 7B and Supplementary Figure S8b) . Reduction of p27 expression had a more modest impact on RhoA-GTP ( Figure 7B and Supplementary Figure S8b) . Under conditions of CSF-1 stimulation, however, the contribution of p27 became more pronounced ( Figure 7B and Supplementary Figure S8b) . Silencing of both PYK2 and p27 in WT cells largely mimicked the effect of p110d inhibition on RhoA-GTP levels, both under basal and stimulated conditions ( Figure 7C and Supplementary Figure S8c) .
The data above suggest that the PYK2/Src-driven mechanism contributes almost solely to inhibition of RhoA activity under basal levels, whereas PYK2 and p27 effects are additive and both contribute to increased RhoA activity upon CSF-1 stimulation.
Discussion
Our data show that PI3K can control itself, through regulation of the PTEN tumour suppressor. This provides the first molecular link between PI3K and its key inactivator. We report that p110d signalling impinges on the previously documented RhoA/PTEN pathway (Li et al, 2005) , which had thus far not been linked to upstream signalling, especially downstream of tyrosine kinases. We document that this RhoA/PTEN pathway is part of a larger signalling network in which p110d is in overall control of PTEN (Figure 8) .
Our results also indicate that signalling by RhoA is a critical node in p110d signalling. Indeed, among the most unexpected findings reported here are the increased basal level of RhoA-GTP activity upon p110d inactivation, and the restoration of the biological defects induced by p110d inactivation by ROCK kinase inhibition. Increased levels of RhoA were found in diverse p110d-expressing cells such as macrophages, breast cancer cell lines and neurons. In these cells, the overall pattern of dynamic changes in RhoA-GTP levels following Tyr kinase receptor (CSF1-R, EGF-R) stimulation was not affected upon p110d inactivation, but the levels of RhoA-GTP remained consistently above those of cells with active p110d (Figure 3C ). RhoA is important for cell body (1 h at 1 mM) were stimulated with CSF-1 for 10 min, followed by measurement of RhoA-GTP levels. (B) BMMs, transfected with siRNA either to PYK2 or p27, were stimulated with CSF-1 (30 ng/ml) for 10 min, followed by measurement of RhoA-GTP levels. (C) BMMs were transfected with siRNA to PYK2 and p27, or negative control siRNA, followed by determination of RhoA-GTP levels. (Ridley, 2001; Sahai and Marshall, 2002) and tight control of this GTPase is critical for efficient cell migration and chemotaxis (Ridley, 2001) . Elevated levels of active RhoA are incompatible with directional cell migration as they prevent membrane protrusion and cell polarity (Nobes and Hall, 1999; Arthur and Burridge, 2001; Ridley, 2001; Raftopoulou and Hall, 2004; Pixley et al, 2005; Wong et al, 2006) .
That PI3K can be involved in keeping RhoA-GTP levels down has been suggested by the observation that treatment of neutrophils with the pan-PI3K inhibitor LY294002 enhances basal RhoA activity to levels reaching fMLPstimulated RhoA activity (Xu et al, 2003) . No explanation for this observation had been put forward at the time, but the notion that neutrophils have high levels of p110d (Vanhaesebroeck et al, 1997) makes it likely that this isoform of PI3K contributes to the effect of LY294002 on RhoA-GTP levels in these cells.
A number of pathways could potentially explain this p110d-dependent increase in levels of RhoA-GTP under basal conditions. Rac and Rho can suppress each others' activity, via several possible mechanisms (Sander et al, 1999; Ridley, 2001; Burridge and Wennerberg, 2004; Raftopoulou and Hall, 2004) . In BMMs, we did not observe such inverse correlation. Indeed, under basal conditions of p110d inhibition, Rac1-GTP levels were unaltered while RhoA activity was increased ( Figure 3B and C). We provide evidence for two mechanisms that contribute to the increased levels of RhoA-GTP upon p110d inactivation. The first one involves decreased binding of the p27 cyclin-dependent kinase inhibitor to cytosolic RhoA upon p110d inhibition ( Figure 6B ; summarised in Figure 8 ). Indeed, cytosolic p27 can bind RhoA, and prevent its activation by interfering with its binding to GEFs (Besson et al, 2004b) . Thus, upon p110d inactivation, RhoA in the cytosol is not bound to p27 and has therefore more chance to interact with its RhoGEFs, facilitating its GTP loading. A second mechanism for increased RhoA-GTP upon p110d inactivation is reduced activation of Tyr kinases such as PYK2 and Src, leading to reduced p190RhoGAP activity ( Figure  5C , and D; summarised in Figure 8 ). At present, we cannot exclude that other GAPs, such as ARAP3, a recently identified PIP 3 /Rap-dependent RhoA-GAP (Krugmann et al, 2002; Donald et al, 2004) , are also under the control of p110d.
Our data indicate that RhoA signalling downstream of p110d acts through another master regulator, namely PTEN. Indeed, PTEN lipid phosphatase activity was increased upon p110d inactivation ( Figure 2C and E), correlating with increased Tyr phosphorylation of PTEN ( Figure 2B and D) . The effects of p110d inactivation on PTEN phosphorylation and activity were also reversed by the Y27632 ROCK inhibitor. Our results are in line with the evidence presented by Li et al (2005) that RhoA is upstream of PTEN, and mediates PTEN phosphorylation and activation through ROCK (Li et al, 2005; Meili et al, 2005) . Dominant-negative RhoA mutants have no effect in PTEN-null cells (Sanchez et al, 2005) , further demonstrating a link between these two proteins. At present, it is not clear how ROCK activates PTEN, and whether it directly phosphorylates PTEN and/or how it controls Tyr kinases. It is of interest to note that ROCK has also been implicated in the induction of Tyr phosphorylation of proteins (such as FAK) in other cell systems (Sinnett-Smith et al, 2001; Yagi et al, 2006) . Whatever the mechanism of PTEN activation by ROCK, the observation that treatment with inhibitors of ROCK or PTEN partially restored Akt phosphorylation in d D910A/D910A BMMs suggests that negative regulation of PTEN lipid phosphatase activity is a key function of p110d. The fact that inhibition of ROCK recovered all defective phenotypes (polarisation, chemotaxis, Akt phosphorylation, DNA synthesis) in d D910A/D910A BMMs while in parallel blocked the hyperactivation of PTEN in these cells is consistent with a feedback loop in which p110d keeps RhoA and PTEN in check to exert its biological effects (Figure 8) .
It is unclear whether PI3K isoforms other than p110d can also negatively regulate RhoA. Preliminary data indicate that heterozygous inactivation of p110a in BMMs does not affect GTP loading of RhoA (data not shown). At this point, though, it appears that the PIP 3 produced by non-p110d PI3K isoforms does not negatively affect PTEN. This is suggested by the following observations: in the absence of p110d activity, other PI3Ks still produce PIP 3 upon CSF-1 stimulation, given that Akt becomes activated (Figure 2A) . The finding that pharmacological blockade of PTEN further increased Akt phosphorylation in d D910A/D910A cells indicates that this PIP 3 does not efficiently inhibit PTEN (Figure 2A ). This is in line with the observation of unaltered PTEN activity upon CSF-1 stimulation of d D910A/D910A cells, despite the fact that one expects PIP 3 to be produced by non-p110d PI3Ks under those conditions ( Figure 2C ). These results suggest an isoform-selective role for p110d in the negative regulation of PTEN. How such isoform-selective signalling could be achieved is not clear at the moment, but may relate to isoform-selective protein kinase activity (Vanhaesebroeck et al, 1999a) , compartmentalised signalling by class IA PI3Ks and other mechanisms (Vanhaesebroeck et al, 2001 (Vanhaesebroeck et al, , 2005 . Figure 8 Schematic representation of the p110d-RhoA-PTEN signalling pathway described in the text. p110x refers to class I PI3K isoforms other than p110d. Indeed, the notion that inhibition of PTEN leads to increased PIP 3 /P-Akt in cells with inactive p110d suggests that PTEN impinges on the PIP 3 produced by the remaining active class I PI3K isoforms in these cells (p110a, p110b or p110g). This implies that this pathway has the intrinsic capacity for indirect crosstalk between the class I PI3K isoforms.
In summary, our work has uncovered a RhoA-mediated pathway by which p110d PI3K keeps PTEN lipid phosphatase activity in check through a mechanism involving RhoA and ROCK. This pathway is critical for p110d to exert its biological functions, including regulation of CSF-1-induced cell polarisation, chemotaxis and DNA synthesis. Our data also uncover a major role of p110d in regulating RhoA activity. It will be important in future work to assess the role of other class IA PI3K isoforms in the regulation of RhoA, especially in cell types which express low levels of p110d.
Materials and methods
Materials
The PTEN inhibitor 3-hydroxypicolinate vanadium(IV)complex (VO-OHpic) (Rosivatz et al, 2007) was provided by Dr Rudiger Woscholski, Imperial College, London. Polyclonal rabbit antibodies to PYK2 (sc-9019), CSF-1R (sc-692), p110b (sc-602, used for western blots), p110d (sc-7176; used for western blot), goat polyclonal to PTEN (N19) and the monoclonal anti-RhoA antibody were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The antibodies against the PI3K subunits used for immunoprecipitation have been described previously (Vanhaesebroeck et al, 1999b) . Upstate Biotechnology was the source of rabbit polyclonal anti-p85 (06-195), monoclonal anti-Rac1, the Rac1 activation assay kit (including GST-fusion p21-binding domain of PAK1 (GST-PBD) bound to glutathione-Agarose and lysis/wash buffer), monoclonal antip190RhoGAP and anti P-Tyr (4G10). GST-RBD and cell-permeable C3-transferase were from Cytoskeleton Inc. Phospho-specific (T308 and S473) Akt and anti-total Akt antibodies, anti-P-Src (Tyr418), polyclonal antibodies against P-PTEN (S380/T382/T383) and antitotal PTEN were from New England Biolabs. Other sources for reagents were as follows: monoclonal anti-PIP 3 IgG (Echelon Biosciences), rat anti-mouse F4/80-FITC (Serotec), PE anti-mouse CSF-1R (eBioscience), anti-rabbit P-MLC(S19) (Biosource), CSF-1 (Peprotech), rhodamine-phalloidin and Slow Fade Antifade kit (Molecular Probes), Y27632 and H1152 (Calbiochem-Novabiochem), ECL western blotting kit and protein A-or G-Sepharose (AmershamPharmacia). PYK2, p27 siRNA smart pools and negative control siRNA pool were from Dharmacon and Interferin transfection reagent from PolyPlus-Transfection. All other chemicals were obtained from standard commercial sources at the highest grade available.
Isolation and culture of BMMs
BMMs were derived from at least three 6-to 8-week-old mice per experiment and pooled. Cells were seeded on bacteriological plastic plates at 10 6 cells/ml in macrophage growth medium consisting of RPMI 1640 (Gibco-Invitrogen Ltd, Paisley, UK), 1 mM sodium pyruvate (Gibco), 1 Â non-essential amino acids (Gibco), 0.029 mM 2-mercaptoethanol (Sigma), 10% heat-inactivated bovine Ultra low IgG FCS (Gibco) supplemented with 10% L-cell-conditioned medium as a source of CSF-1. After 3 days, nonadherent cells were collected and either cryogenically stored in FCS containing 10% DMSO or seeded at 6-8 Â10 5 cells/ml on bacteriological plates and cultured for 4 days before use. Cells were detached using EDTA, centrifuged at 1000 g, resuspended in macrophage growth medium and seeded for the experiments. All results were obtained from cells that had been cultured for no longer than 10 days after dissection. In all experiments described below (unless otherwise specified), the medium was changed to macrophage starvation medium ( ¼ macrophage growth medium without L-cell-conditioned medium) 16-20 h prior to the actual experiments. Unless otherwise indicated, the concentration of CSF-1 for cell stimulation was 30 ng/ml. siRNA transfection Cells were seeded for the experiments as described above and transfected the next day with siRNA to PYK2 and/or p27 (final concentration of each siRNAi was 50 nM) using Interferin transfection reagent, according to the manufacturers' instructions. Experiments were performed 4 days after transfection.
Supplementary data
Supplementary data are available at The EMBO Journal Online (http://www.embojournal.org).
